XML 34 R11.htm IDEA: XBRL DOCUMENT

Other Balance Sheet Details

6 Months Ended

Jun. 30, 2024

Other Balance Sheet Details [Abstract]

Inventory consisted of the following:


(in millions)	June 30, 2024		December 31, 2023
Raw materials	$	21.3	$	21.5
Work in process	12.0		9.7
Finished goods	10.4		12.3
	43.7		43.5
Less inventory reserves	(1.2)		(5.2)
Total inventory	$	42.5	$	38.3

Accounts payable and accrued liabilities consisted of the following:


(in millions)	June 30, 2024		December 31, 2023
Sales rebates and reserves	$	121.7	$	139.3
Accrued employee related costs	59.8		86.2
Current branded prescription drug fee	35.3		45.7
Accrued development costs	34.7		44.3

Accounts payable and other accrued liabilities	107.2		133.3
Total accounts payable and accrued liabilities	$	358.5	$	448.8

Other noncurrent liabilities consisted of the following:


(in millions)	June 30, 2024		December 31, 2023
Noncurrent income taxes payable	$	111.0	$	96.0
Noncurrent branded prescription drug fee	30.1		10.3
Total other noncurrent liabilities	$	141.1	$	106.3

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows.


(in millions)	June 30, 2024		June 30, 2023
Cash and cash equivalents	$	139.7	$	160.2
Restricted cash included in other noncurrent assets	8.0		8.0
Total cash, cash equivalents and restricted cash	$	147.7	$	168.2